The Nephrotoxicity of Vancomycin

被引:332
作者
Filippone, E. J. [1 ,2 ]
Kraft, W. K. [3 ]
Farber, J. L. [4 ]
机构
[1] Thomas Jefferson Univ, Dept Med, Sydney Kimmel Coll Med, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Div Nephrol, Sydney Kimmel Coll Med, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Sydney Kimmel Coll Med, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Dept Pathol, Sydney Kimmel Coll Med, Philadelphia, PA 19107 USA
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; ACUTE KIDNEY INJURY; MINIMUM INHIBITORY CONCENTRATION; BLOOD-STREAM INFECTIONS; HIGH-DOSE VANCOMYCIN; PIPERACILLIN-TAZOBACTAM; TROUGH CONCENTRATIONS; CONCOMITANT VANCOMYCIN; RETROSPECTIVE ANALYSIS; INTERMITTENT INFUSION;
D O I
10.1002/cpt.726
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vancomycin use is often associated with nephrotoxicity. It remains uncertain, however, to what extent vancomycin is directly responsible, as numerous potential risk factors for acute kidney injury frequently coexist. Herein, we critically examine available data in adult patients pertinent to this question. We review the pharmacokinetics/ pharmacodynamics of vancomycin metabolism. Efficacy and safety data are discussed. The pathophysiology of vancomycin nephrotoxicity is considered. Risk factors for nephrotoxicity are enumerated, including the potential synergistic nephrotoxicity of vancomycin and piperacillin-tazobactam. Suggestions for clinical practice and future research are given.
引用
收藏
页码:459 / 469
页数:11
相关论文
共 100 条
[2]  
[Anonymous], 2017, ANTIMICROB AGENTS CH
[3]  
[Anonymous], CLIN INFECT DIS
[4]  
[Anonymous], J PHARM PRACT
[5]  
[Anonymous], CLIN INFECT DIS S1
[6]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[7]   Vancomycin therapeutics and monitoring: a contemporary approach [J].
Avent, M. L. ;
Vaska, V. L. ;
Rogers, B. A. ;
Cheng, A. C. ;
van Hal, S. J. ;
Holmes, N. E. ;
Howden, B. P. ;
Paterson, D. L. .
INTERNAL MEDICINE JOURNAL, 2013, 43 (02) :110-119
[8]   Augmented renal clearance in septic patients and implications for vancomycin optimisation [J].
Baptista, Joao Pedro ;
Sousa, Eduardo ;
Martins, Paulo J. ;
Pimentel, Jorge M. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (05) :420-423
[9]   Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies [J].
Barriere, Steven L. ;
Stryjewski, Martin E. ;
Corey, G. Ralph ;
Genter, Fredric C. ;
Rubinstein, Ethan .
BMC INFECTIOUS DISEASES, 2014, 14
[10]   Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy [J].
Barth, RH ;
DeVincenzo, N .
KIDNEY INTERNATIONAL, 1996, 50 (03) :929-936